New therapeutic protocols based on the expected synergistic action of molecules capable of blocking activation the HGF/Met axis, used in combination withBcr-Abl inhibitors (CML) or JAK inhibitors (MPNs), can now be envisioned. Here, HGF is linked to chronic myelogenous leukemia, BCR-ABL1 positive.